Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday and set a price target of $12.00. The company’s shares closed yesterday at $9.25.
According to TipRanks, Gerberry is a 3-star analyst with an average return of -1.6% and a 44.67% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Exelixis, Jazz Pharmaceuticals, and Teva Pharmaceutical.
In addition to Bank of America Securities, Teva Pharmaceutical also received a Buy from Barclays’s Balaji Prasad in a report issued yesterday. However, today, Goldman Sachs maintained a Hold rating on Teva Pharmaceutical (NYSE: TEVA).
See the top stocks recommended by analysts >>
The company has a one-year high of $11.45 and a one-year low of $7.09. Currently, Teva Pharmaceutical has an average volume of 14.21M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
Read More on TEVA:
- Teva Pharamceutical (NYSE:TEVA) Surges After Earnings Report
- Teva Pharmaceutical Industries Limited (TEVA) Q2 Earnings Cheat Sheet
- Mizuho biotech/biopharma analyst to hold analyst/industry conference call
- Teva, Alvotech to expand strategic biosimilars partnership agreement
- Exelixis announces settlement of CABOMETYX patent litigation with Teva
